Byhealth (300146) Q2 2026 earnings summary

Executive summary

• Revenue for H1 2026 reached ¥3.67 billion, up 3.94% year-over-year, while net profit attributable to shareholders fell 18.11% to ¥603 million.

• Main business income grew 5.00% year-over-year, with online channels up 15.51% and offline down 4.85%.

• Gross margin improved to 70.62%, and the company continued to invest in R&D and digital transformation.

• The company maintained a leading position in the dietary supplement industry, focusing on scientific nutrition, product innovation, and global expansion.

Financial highlights

• Operating income: ¥3.67 billion, up 3.94% year-over-year.

• Net profit attributable to shareholders: ¥603 million, down 18.11% year-over-year.

• Operating cash flow: ¥178 million, down 72.21% year-over-year.

• Gross margin: 70.62%, up 1.11 percentage points year-over-year.

• Basic and diluted EPS: ¥0.36, down 16.28% year-over-year.

Outlook and guidance

• The company will continue to focus on scientific nutrition, digital transformation, and global market expansion.

• Investment in R&D and digital infrastructure will be maintained to drive product innovation and operational efficiency.

• No interim dividend, bonus shares, or capital reserve to share capital conversion planned for the half-year.